# Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

> **NCT03211858** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 597 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin aspart
- **DRUG:** NovoLog/NovoRapid
- **DRUG:** Insulin glargine (HOE901)

## Key facts

- **NCT ID:** NCT03211858
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-02
- **Primary completion:** 2018-07-16
- **Final completion:** 2019-01-12
- **Target enrollment:** 597 (ACTUAL)
- **Last updated:** 2022-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03211858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03211858, "Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03211858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*